

PRESS RELEASE

**Appointment of Mathieu Simon, MD, to the position of
Senior vice-president of Collectis Group**

Paris, 2 April 2012 - Collectis (Alternext: ALCLS), the French specialist in genome engineering has announced the appointment of Dr Mathieu Simon to the position of Senior vice-president.

Within the Collectis group Mathieu Simon is in charge of developing therapeutic activities. In this capacity he will shortly be nominated president of each of the dedicated subsidiaries: Collectis Therapeutics, Ectycell and Cellartis. Mathieu Simon will be responsible for the "Collectis stem cell" business unit, created in 2011, which regroups the Cellartis and Ectycell subsidiaries, dedicated to "stem cell" activity.

Mathieu Simon is a member of Collectis's executive committee.

André Choulika, chairman and chief executive officer of Group Collectis, has expressed satisfaction at the arrival of Mathieu Simon, an internationally known expert in the pharmaceutical industry. "The arrival of Mathieu Simon will significantly enhance the capacity of Collectis to become, in the near future, an essential economic actor. We expect him to play an active role in the generation of new commercial actions, to help launch innovative and efficient products on the market, and to fully participate in the growth of the Group's turnover". As for him, Dr Mathieu Simon has declared that "I take up this new challenge with enthusiasm. Collectis is one of the most emblematic companies in the biotech sector and I happily join its ranks whose teams have built themselves a good reputation for scientific skill and innovative dynamism".

A 1982 graduate of the Paris Faculté de médecine, Dr Mathieu Simon has been active in the pharmaceutical field where, in an international career, he excelled at the highest level.

After having been *Marketing & Sales Director* at Wyeth France, Mathieu Simon became *Group VP Marketing / Clinical Affairs* for Wyeth Pharmaceuticals in the United States, where he was responsible for the marketing strategy of 5 business units. Mathieu Simon was then tasked with heading several of the most important regional subsidiaries of Group Wyeth (Benelux, Italy, Greece, The Balkans), with responsibility over several hundred million euros in turnover, as well as supervising 2 000 employees.

In 2010, Mathieu Simon was appointed *Pharma Global Operations Senior vice president* for Groupe Pierre Fabre Médicament.

Since 2011, he had been acting as advisor to financial institutions as well as to other companies of the sector.

**About Collectis**

Collectis improves the quality of life by applying its know-how in genome engineering to a broad range of applications, including human therapeutics, biological and agricultural research. Collectis is listed on the Paris NYSE-Euronext Alternext market (code: ALCLS).

For more information, visit www.collectis.com.

Disclaimer

This message, and the information it contains, is neither an offer to the public, nor a sales or subscription proposal for Collectis shares in any country whatsoever.

For further information, please contact:**Collectis**

Philippe Valachs
Secretary General
Tel : +33 (0)1 81 69 16 00
media@collectis.com

Profile PR

Press relations
Leslie Boutin
Tél : +33 (0)1 56 26 72 33
lboutin@profilepr.fr